Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 200 Results

Title
Intervention Indication Therapeutic Area Year Actions
Apalutamide with primary radiation therapy for treating high-risk, localised or locally advanced prostate cancer Apalutamide (Erleada; ARN-509) , Primary radiation therapy Prostate cancer Male Reproductive Cancer 2022 View  |  Download
AR101 for peanut allergy in children aged 1 – 3 years Palforzia (AR101) Peanut allergy Immunology 2022 View  |  Download
ASTX727 for acute myeloid leukaemia ASTX727 Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2022 View  |  Download
Ataluren for Duchenne Muscular Dystrophy with nonsense mutation Ataluren (Translarna; PTC 124; PTC-124; PTC124) Duchenne muscular dystrophy (DMD) Genetic Disorders , Musculoskeletal System 2022 View  |  Download
Atezolizumab adjuvant therapy for treating renal cell carcinoma in people at high risk of developing metastasis following nephrectomy Atezolizumab (Tecentriq; MPDL3280A) Renal cell carcinoma (RCC) Renal Cancer 2022 View  |  Download
Atezolizumab for previously untreated recurrent or advanced non-small cell lung cancer unsuitable for platinum-doublet chemotherapy Atezolizumab (Tecentriq; MPDL3280A) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2022 View  |  Download
Atezolizumab with bevacizumab for patients with resected or ablated hepatocellular carcinoma who are at high risk for disease recurrence Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2022 View  |  Download
Atezolizumab with cabozantinib for advanced renal cell carcinoma after 1 therapy Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) Renal cell carcinoma (RCC) Renal Cancer 2022 View  |  Download
Atezolizumab with cabozantinib for previously treated metastatic castration-resistant prostate cancer Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) Prostate cancer Male Reproductive Cancer 2022 View  |  Download
Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-containing chemotherapy and one programmed death-ligand 1 checkpoint inhibitor Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2022 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications